Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Shao-Huan LanChi-Kuei HsuShen-Peng ChangLi-Chin LuChih-Cheng LaiPublished in: Annals of medicine (2023)
IL-1 blockade does not provide increased survival benefits in hospitalized patients with COVID-19, but it may reduce the need for MV. Furthermore, it is a safe agent for use in the treatment of COVID-19.>.